As previously reported (31, 33), treatment with LRRK2-IN-1 resulted in a substantial reduction in both total DCLK1 and phospho-DCLK1 expression levels in all HNSCC cell lines analyzed (Figure 1B). This evidence concerns the gene LRRK2 and head and neck squamous cell carcinoma.